Skip to main content
SpringerLink
Log in

Prevention and Treatment of Osteoporosis in Postmenopausal Women

Defining the Role of Alendronate

  • Drugs In Disease Management
  • Published:
Disease Management & Health Outcomes

Abstract

Postmenopausal osteoporosis is characterized by an increased rate of bone turnover accompanied by a reduction in bone mineral density (BMD) that results in an increased risk of fracture, especially of the vertebrae, hip, or wrist. Alendronate (Fosamax®, Fosamax Once-Weekly®), an oral bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism, is a first-line therapy for the management of postmenopausal women with, or at risk of developing, osteoporosis.

Alendronate produces sustained increases in BMD and reductions in bone turnover from baseline, and reduces the risk of vertebral, hip, wrist, and other fractures in women with postmenopausal osteoporosis. It also prevents bone loss, and reduces the risk of radiographic or clinical vertebral fracture in postmenopausal osteopenia. Provided administration instructions are followed, alendronate is generally well tolerated. Adverse events are usually transient and are associated with the upper gastrointestinal tract (abdominal pain, nausea, acid regurgitation, dyspepsia); moreover, the incidence of these adverse events with alendronate was similar to those with placebo. More serious events (esophagitis, gastric or duodenal ulceration or bleeding) are uncommon. Once-weekly formulations are as effective and as well tolerated as once-daily alendronate in postmenopausal women.

Pharmacoeconomic evaluations suggest that alendronate is a viable treatment option in postmenopausal osteoporosis. The reduction in fracture-related healthcare utilization seen with alendronate results in decreased direct costs, including inpatient or long-term care. Markov state-transition models suggest that this could at least partially offset costs incurred with alendronate therapy. Treatment of women with osteoporosis aged 65 years and older, and postmenopausal women with a previous osteoporotic fracture, are cost-effective strategies. Alendronate is also likely to increase quality-adjusted life-years in any postmenopausal women with osteoporosis.

In conclusion, clinical and economic data support the use of alendronate in postmenopausal osteoporosis. It effectively reduces bone turnover, increases BMD, and reduces the risk of osteoporotic fracture in postmenopausal women with established osteoporosis, especially older women with a higher risk of fracture. Although its cost effectiveness in postmenopausal women with osteopenia is not clearly established, alendronate is clinically effective in these patients. In addition, it is generally well tolerated when taken as recommended. Consequently, alendronate should be considered a therapy of choice in the prevention and treatment of osteoporosis in postmenopausal women.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Table IV
Fig. 2
Table V

Similar content being viewed by others

Notes

  1. Use of tradenames is for product identification purposes only and does not imply endorsement.

References

  1. Anon. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993 Jun; 94(6): 646–50

    Article  Google Scholar 

  2. National Institutes of Health. Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus Statement 2000 Mar 27-29; 17 (1–36)

    Google Scholar 

  3. Newman ED. A schema for effective osteoporosis management. Outcomes of the Geisinger Health System osteoporosis program. Dis Manage Health Outcomes 2003; 11(10): 611–6

    Article  Google Scholar 

  4. Mahakala A, Thoutreddy S, Kleerekoper M. Prevention and treatment of postmenopausal osteoporosis. Treat Endocrinol 2003; 2(5): 331–45

    Article  PubMed  CAS  Google Scholar 

  5. Institute For Clinical Systems Improvement. Health Care guideline: diagnosis and treatment of osteoporosis [online]. Available from URL: http://www.icsi.org [Accessed 2003 Jul 3]

  6. Ravn P. Bisphosphonates for prevention of postmenopausal osteoporosis. Dan Med Bull 2002 Feb; 49(1): 1–18

    PubMed  CAS  Google Scholar 

  7. American Society for Bone and Mineral Research. Regarding the results of the women’s health initiative HRT trial [online]. Available from URL: http://www.asbmr.org/Pages/WHI.htm [Accessed 2003 Apr 15]

  8. U.S. Prevantative Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2002 Nov 19; 137(10): 834–9

    Google Scholar 

  9. US Food and Drug Administration. FDA Fact Sheet: FDA approves new labeling and provides new advice to postmenopausal women who use or who are considering using estrogen and estrogen with progestin [online]. Available from URL: http://www.fda.gov/bbs/topics/factsheets/2003/fsl.html [Accessed 2003 Apr 15]

  10. Lagro-Janssen T, Rosser WW, van Weel C. Breast cancer and hormone-replacement therapy: up to general practice to pick up the pieces. Lancet 2003 Aug 9; 362(9392): 414–5

    Article  PubMed  Google Scholar 

  11. Jeal W, Barradell LB, McTavish D. Alendronate: a review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Drugs 1997; 53(3): 415–34

    Article  PubMed  CAS  Google Scholar 

  12. Sharpe M, Noble S, Spencer CM. Alendronate: an update of its use in osteoporosis. Drugs 2001; 61(7): 999–1039

    Article  PubMed  CAS  Google Scholar 

  13. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000 Feb; 12(1): 1–12

    CAS  Google Scholar 

  14. Cummings SR. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis — status report. Osteoporos Int 1998; 8 Suppl. 4: 1–85

    Google Scholar 

  15. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 2002 Sep 17; 137 (6): 526-8

  16. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002 Jun 1; 359(9321): 1929–36

    Article  PubMed  Google Scholar 

  17. National Osteoporosis Foundation. Physician’s guide to prevention and treatment of osteoporosis [online]. Available from URL: http://www.nof.org/physguide/index.htm [Accessed 2003 Oct 23]

  18. Kanis JA, Glüer C-C, for the Committee of Scientific Advisers International Osteoporosis Foundation. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 2000; 11(3): 192–202

    Article  PubMed  CAS  Google Scholar 

  19. Ettinger MP. Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Arch Intern Med 2003 Oct 13; 163(18): 2237–46

    Article  PubMed  Google Scholar 

  20. Holick MF, Krane SM. Introduction to bone and mineral metabolism. In: Braunwald E, Fauci AS, Isselbacher KJ, et al, editors. Harrison’s Principles of Internal Medicine. 15th ed. New York: McGraw-Hill Companies, Inc., 2001; 2: Available at URL: http://www.harrisononline.com

    Google Scholar 

  21. Lindsay R, Cosman F. Osteoporosis. In: Braunwald E, Fauci AS, Isselbacher KJ, et al, editors. Harrison’s Principles of Internal Medicine [online]. 15th ed. New York: McGraw-Hill Corporation Inc., 2001; 2: Available at URL: http://www.harrisononline.com

    Google Scholar 

  22. Cranney A, Guyatt G, Griffith L, et al. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002 Aug; 23(4): 570–8

    Article  PubMed  CAS  Google Scholar 

  23. Body JJ. Management of primary osteoporosis. Acta Clin Belg 2002 Sep–2002 31; 57(5): 277–83

    PubMed  CAS  Google Scholar 

  24. International Osteoporosis Foundation. The facts about osteoporosis and its impact [online]. Available from URL: http://www.osteofound.org [Accessed 2003 Jul 14]

  25. Cooper C. Epidemiology of osteoporosis. Osteoporos Int 1999; 9 Suppl. 1: S2–8

    Article  PubMed  Google Scholar 

  26. Looker AC, Orwoll ES, Johnston Jr CC, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997 Nov; 12(11): 1761–8

    Article  PubMed  CAS  Google Scholar 

  27. Looker AC, Johnston Jr CC, Wahner HW, et al. Prevalence of low femoral bone density in older U.S. women from NHANES III. J Bone Miner Res 1995 May; 10(5): 796–802

    Article  PubMed  CAS  Google Scholar 

  28. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. Results from the National Osteoporosis Risk Assessment. JAMA 2001 Dec; 286(22): 2815–22

    Article  PubMed  CAS  Google Scholar 

  29. Melton LJ, Chrischilles EA, Cooper C, et al. How many women have osteoporosis? J Bone Miner Res 1992; 7(9): 1005–10

    Article  PubMed  Google Scholar 

  30. Ho SC, Lau EMC, Woo J, et al. The prevalence of osteoporosis in the Hong Kong Chinese female population. Maturitas 1999 Aug 16; 32: 171–8

    Article  PubMed  CAS  Google Scholar 

  31. Limpaphayom KK, Taechakraichana N, Jaisamrarn U, et al. Prevalence of osteopenia and osteoporosis in Thai women. Menopause 2001 Jan–Feb; 8(1): 65–9

    Article  PubMed  CAS  Google Scholar 

  32. vanderVoort DJM, Brandon S, Dinant GJ, et al. Screening for osteoporosis using easily obtainable biometrical data: diagnostic accuracy of measured, self-reported and recalled BMI, and related costs of bone mineral density measurements. Osteoporos Int 2000; 11(3): 233–9

    Article  CAS  Google Scholar 

  33. Filip RS, Zagórski J. Bone mineral density and osteoporosis in rural and urban women. Epidemiological study of the Lublin region (Eastern Poland). Ann Agric Environ Med 2001; 8: 221–6

    PubMed  CAS  Google Scholar 

  34. Baron JA, Farahmand BY, Weiderpass E, et al. Cigarette smoking, alcohol consumption, and risk of hip fracture in women. Arch Intern Med 2001 Apr 9; 161(7): 983–8

    Article  PubMed  CAS  Google Scholar 

  35. Hoerger TJ, Downs KE, Lakshmana MC, et al. Healthcare use among US women aged 45 and older: total costs and costs for selected postmenopausal risks. J Women Health Gend Based Med 1999; 8(8): 1077–89

    Article  CAS  Google Scholar 

  36. Gabriel SE, Tosteson ANA, Leibson CL, et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 2002; 13(4): 323–30

    Article  PubMed  CAS  Google Scholar 

  37. Max W, Sinnot P, Kao C, et al. The burden of osteoporosis in California, 1998. Osteoporos Int 2002; 13(6): 493–500

    Article  PubMed  CAS  Google Scholar 

  38. Wiktorowicz ME, Goeree R, Papaioannou A, et al. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int 2001; 12(4): 271–8

    Article  PubMed  CAS  Google Scholar 

  39. Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 1998; 8(6): 611–7

    Article  PubMed  CAS  Google Scholar 

  40. Newman ED, Ayoub WT, Starkey RH, et al. Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int 2003; 14(2): 146–51

    PubMed  CAS  Google Scholar 

  41. Royal College of Physicians, Bone and Tooth Society of Great Britain. Osteoporosis: clinical guidelines for prevention and treatment. Update on pharmacological interventions and an algorithm for management [online]. Available from URL: http://www.rcplondon.ac.uk/pubs/wp_osteo_update.html [Accessed 2003 Jul 3]

  42. Gallagher JC, Ettinger B, Gass MLS, et al. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause 2002; 9(2): 84–101

    Google Scholar 

  43. World Orthopedic Osteoporosis Organisation. Recommendations for the care of the osteoporotic fracture patient to reduce the risk of future fracture [online]. Available from URL: http://www.osteofound.org/health_professionals/consensus_guidelines/download/wooo.pdf [Accessed 2003 Jul 4]

  44. American Association of Clinical Endocrinologists. 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract 2001; 7(4): 293–312

    Google Scholar 

  45. Electronic Medicines Compendium. FOSAMAX Once Weekly 70mg Tablets (alendronate sodium). UK summary of product characteristics. Merck Sharp & Dohme Limited, Hoddeston, UK [online]. Available from URL: http://emc.vhn.net/public/ [Accessed 2003 Jul 7]

  46. Electronic Medicines Compendium. FOSAMAX (alendronate sodium). UK summary of product characteristics. Merck Sharp & Dohme Limited, Hoddeston UK [online]. Available from URL: http://emc.vhn.net/public/ [Accessed 2003 Jul 7]

  47. FOSAMAX (Alendronate sodium tablets). US Package insert. Merck & Co. Inc., Whitehouse Station (NJ) [online]. Available from URL: http://www.fosamax.com [Accessed 2003 Jul 7]

  48. Actonel (risedronate sodium). Actonel 5mg film-coated tablets. UK patient information leaflet. Proctor & Gamble Pharmaceuticals UK Ltd, Staines, UK, 2001 Jun

    Google Scholar 

  49. Actonel (risedronate sodium). Actonel 30mg film-coated tablets. UK patient information leaflet. Proctor & Gamble Pharmaceuticals UK Ltd, Staines, UK, 2001 Nov

    Google Scholar 

  50. Actonel (risedronate sodium tablets). US package insert. Proctor & Gamble Pharmaceuticals, Cincinnati (OH) [online]. Available from URL: http://www.actonel.com [Accessed 2003 Jul 7]

  51. European Agency for the Evaluation of Medicinal Products. EVISTA (raloxifene hydrochloride). European package leaflet. [online]. Available from URL: http://www.eudra.org/humandocs/Humans/EPAR/Evista/EvistaM.htm [Accessed 2003 Jul 7]

  52. Evista (raloxifene hydrochloride). US package insert. Eli Lilly and Company, Indianapolis (IN) [online]. Available from URL: http://pi.lilly.com/us/evistapi.pdf [Accessed 2003 Jul 7]

  53. FORTEO (teriparatide (rDNA origin) injection. US package insert. Eli Lilly and Company, Indianapolis (IN) [online]. Available from URL: http://pi.lilly.com/us/forteo-pi.pdf [Accessed 2003 Jul 7]

  54. European Agency for the Evaluation of Medicinal Products. FORSTEO (teriparatide). European Package leaflet [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/forsteo/forsteoM.htm [Accessed 2003 Jul 7]

  55. Russell RGG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999; 9 Suppl. 1: S66–80

    Article  PubMed  Google Scholar 

  56. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999 Oct; 282(14): 1344–52

    Article  PubMed  CAS  Google Scholar 

  57. Dempster DW. The impact of bone turnover and bone-active agents on bone quality: focus on the hip. Osteoporos Int 2002; 13(5): 349–52

    Article  PubMed  CAS  Google Scholar 

  58. Tucci JR, Tonino RP, Emkey RD, et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996 Nov; 101(5): 488–501

    Article  PubMed  CAS  Google Scholar 

  59. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999; 9(5): 461–8

    Article  PubMed  CAS  Google Scholar 

  60. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995 Nov 30; 333(22): 1437–43

    Article  PubMed  CAS  Google Scholar 

  61. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996; 18(2): 141–50

    Article  PubMed  CAS  Google Scholar 

  62. Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999 Dec 21; 131(12): 935–42

    PubMed  CAS  Google Scholar 

  63. Ravn P, Weiss SR, JA Rodriguez-Portales, et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. J Clin Endocrinol Metab 2000 Apr; 85(4): 1492–7

    Article  PubMed  CAS  Google Scholar 

  64. McClung M, Wasnich R, Omizo M, et al. Resolution of effect following alendronate: six-year results from the early postmenopausal interventional Cohort (EPIC) Study [abstract no. 1037]. J Bone Miner Res 2002 Sep; 17 Suppl. 1: S134

    Google Scholar 

  65. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535–41

    Article  PubMed  CAS  Google Scholar 

  66. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998 Dec 23; 280(24): 2077–82

    Article  PubMed  CAS  Google Scholar 

  67. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000 Nov; 85(11): 4118–24

    Article  PubMed  CAS  Google Scholar 

  68. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997 Dec 8; 157(22): 2617–24

    Article  PubMed  CAS  Google Scholar 

  69. Bone HG, Downs RW, Tucci JR, et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 1997 Jan; 82(1): 265–74

    Article  PubMed  CAS  Google Scholar 

  70. Downs Jr RW, Bone HG, McIlwain H, et al. An open-label extension study of alendronate treatment in elderly women with osteoporosis. Calcif Tissue Int 1999 Jun; 64(6): 463–9

    Article  PubMed  CAS  Google Scholar 

  71. Dunn CJ, Goa KL. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease. Drugs 2001; 61(5): 685–712

    Article  PubMed  CAS  Google Scholar 

  72. Porras A, Denker A, Santhanagopal A, et al. Alendronate and risedronate have similar pharmacokinetic half-lives when analyzed over the same time interval [abstract no. M319]. American Society of Bone and Mineral Research (ASBMR) 25th Annual Meeting; 2003 Sep 19–23; Minneapolis (MN)

    Google Scholar 

  73. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002 Feb; 71(2): 103–11

    Article  PubMed  CAS  Google Scholar 

  74. Watts NB, Lindsay R, Zhengqing L, et al. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int 2003; 14(5): 437–41

    Article  PubMed  CAS  Google Scholar 

  75. Dunn CJ, Fitton A, Sorkin EM. Etidronic acid: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging 1994; 5(6): 446–74

    Article  PubMed  CAS  Google Scholar 

  76. British Medical Association and Royal Pharmaceutical Society of Great Britain. Disodium Etidronate. British National Formulary 2003 Mar; 45: 371

    Google Scholar 

  77. Beauchesne M-F, Miller PF. Etidronate and alendronate in the treatment of postmenopausal osteoporosis. Ann Pharmacother 1999; 33(5): 587–99

    Article  PubMed  CAS  Google Scholar 

  78. Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 1999; 130(5): 431–9

    PubMed  CAS  Google Scholar 

  79. Clemett D, Spencer CM. Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 2000 Aug; 60(2): 379–411

    Article  PubMed  CAS  Google Scholar 

  80. Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000 Jun; 85(6): 2197–202

    Article  PubMed  CAS  Google Scholar 

  81. Wellington K, Plosker GL. Management of postmenopausal osteoporosis: defining the role of raloxifene. Dis Manage Health Outcomes 2003; 11(10): 673–92

    Article  CAS  Google Scholar 

  82. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999 Aug; 282(7): 637–45

    Article  PubMed  CAS  Google Scholar 

  83. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002 Jun 8; 359(9322): 2018–26

    Article  PubMed  CAS  Google Scholar 

  84. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone density: the Women’s Health Initiative randomized trial. JAMA 2003 Oct 1; 290(13): 1729–38

    Article  PubMed  CAS  Google Scholar 

  85. Barrett-Connor E, Wheren LE, Yates J, et al. Rapid loss of hip antifracture efficacy following estrogen cessation: evidence from NORA. Obstet Gynecol 2003; 101 Suppl.: S5

    Article  Google Scholar 

  86. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trial. JAMA 2003 Jun 25; 289(24): 3243–53

    Article  PubMed  CAS  Google Scholar 

  87. Beral V, for the Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–27

    Article  PubMed  CAS  Google Scholar 

  88. Scarabin P-Y, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003 Aug 9; 362(9382): 428–32

    Article  PubMed  CAS  Google Scholar 

  89. Berning B, Coelingh Bennik HJT, Fauser BCJM. Tibolone and its effects on bone: a review. Climacteric 2001; 4: 120–36

    PubMed  CAS  Google Scholar 

  90. British Medical Association and Royal Pharmaceutical Society of Great Britain. Tibolone. British National Formulary 2003 Mar; 45: 358

    Google Scholar 

  91. Sayegh RA, Stubblefield PG. Bone metabolism and the perimenopause: overview, risk factors, screening, and osteoporosis preventive measures. Obstet Gynecol Clin North Am 2002 Sep; 29(3): 495–510

    Article  PubMed  Google Scholar 

  92. Rapuri PB, Gallagher JC, Balhorn KE, et al. Alcohol intake and bone metabolism in elderly women. Am J Clin Nutr 2000; 72: 1206–3

    PubMed  CAS  Google Scholar 

  93. Luckey MM, Gilchrist N, Bone HG, et al. Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. Obstet Gynecol 2003 Apr; 101(4): 711–21

    Article  PubMed  CAS  Google Scholar 

  94. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000 Sep; 85(9): 3109–15

    Article  PubMed  CAS  Google Scholar 

  95. Emkey R, Reid I, Mulloy A, et al. Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women [abstract no.1059]. J Bone Miner Res 2002 Sep; 17 Suppl. 1: S139

    Google Scholar 

  96. Ensrud K, Santora A, Schwartz A, et al. The fracture intervention trial long term extension (FLEX): 3 year interim results [abstract no. SA348]. American Society of Bone and Mineral Research (ASBMR) 25th Annual Meeting; 2003 Sep 19–23; Minneapolis (MN)

    Google Scholar 

  97. Greenspan SL, Schneider DL, McClung MR, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002 May 21; 136(10): 742–6

    PubMed  CAS  Google Scholar 

  98. Bell NH, Bilezikian JP, Bone III HG, et al. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab 2002 Jun; 87(6): 2792–7

    Article  PubMed  CAS  Google Scholar 

  99. Kung AW, Yeung SS, Chu LW. The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study. Calcif Tissue Int 2000 Oct; 67(4): 286–90

    Article  PubMed  CAS  Google Scholar 

  100. McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998 Feb 15; 128(4): 253–61

    PubMed  CAS  Google Scholar 

  101. Sambrook PN, Rodriguez JP, Wasnich RD, et al. Alendronate in the prevention of osteoporosis [abstract no. SA345]. J Bone Miner Res 2002; 17 Suppl. 1

  102. Hosking DJ, Christiansen C, Wasnich RD, et al. Consistency of response to 6-year treatment with alendronate among subgroups [abstract no. SA350]. American Society of Bone and Mineral Research (ASBMR) 25th Annual Meeting; 2003 Sep 10–23; Minneapolis (MN)

    Google Scholar 

  103. Ascott-Evans BH, Guanabens N, Kivinen S, et al. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. Arch Intern Med 2003 Apr 14; 163(7): 789–94

    Article  PubMed  CAS  Google Scholar 

  104. Nevitt MC, Thompson DE, Black DM, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 2000 Jan 10; 160(1): 77–85

    Article  PubMed  CAS  Google Scholar 

  105. Black D, Thompson D, Quandt S, et al. Alendronate reduces risk of vertebral fracture in women with BMD T-scores above -2.5: results from the fracture intervention trial (FIT) [abstract no. P75SU]. Osteoporos Int 2002; 13 Suppl. 1: S27

    Google Scholar 

  106. Quandt S, Thompson D, Schnieder D, et al. Alendronate reduces the risk of clinical vertebral fracture in osteopenic women: data from FIT. J Women Health and Gend Based Med 2001 May; 10(4): 406

    Google Scholar 

  107. Cranney A, Wells G, Willan A, et al. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002 Aug; 23(4): 508–16

    Article  PubMed  CAS  Google Scholar 

  108. Kushida K, Shiraki M, Nakamura T, et al. The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial. Curr Ther Res Clin Exp 2002 Sep; 63(9): 606–20

    Article  CAS  Google Scholar 

  109. Shiraki M, Kushida K, Fukunaga M, et al. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos Int 1999; 10(3): 183–92

    Article  PubMed  CAS  Google Scholar 

  110. Downs Jr RW, Bell NH, Ettinger MP, et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000; 85(5): 1783–8

    Article  PubMed  CAS  Google Scholar 

  111. Schnitzer TJ, Rosen CJ, Bonnick SL, et al. Alendronate vs intranasal calcitonin: 2-year study. J Women Health Gend Based Med 2001 May; 10(4): 404

    Google Scholar 

  112. Sambrook P, Geusens P, Ferrer-Barriendos J, et al. Greater increases in BMD with alendronate compared to raloxifene: results from EFFECT-International [abstract no. SA344]. American Society of Bone and Mineral Research (ASBMR) 25th Annual Meeting; 2003 19–23 Sep; Minneapolis (MN)

    Google Scholar 

  113. Luckey M, Greenspan S, Bone H, et al. Efficacy of Fosamax vs Evista Comparison Trial (EFFECT): results of a randomized, multicenter study [abstract no. SU343]. American Society of Bone and Mineral Research (ASBMR) 25th Annual Meeting; 2003 Sep 19–23; Minneapolis (MN)

    Google Scholar 

  114. Hosking D, Adami S, Felsenberg D, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin 2003; 19(5): 383–94

    Article  PubMed  CAS  Google Scholar 

  115. Merck & Co., Inc. Merck & Co., Inc. launches first large-scale head-to-head comparisons of once weekly therapies for osteoporosis [media release]. 2003 Feb 4

  116. Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002 Oct; 87(10): 4528–35

    Article  PubMed  CAS  Google Scholar 

  117. Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999 Sep; 84(9): 3076–81

    Article  PubMed  CAS  Google Scholar 

  118. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000 Feb; 85(2): 720–6

    Article  PubMed  CAS  Google Scholar 

  119. Tiras MB, Noyan V, Yildiz A, et al. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study. Hum Reprod 2000; 15(10): 2087–92

    Article  PubMed  CAS  Google Scholar 

  120. Palomba S, Orio Jr F, Colao A, et al. Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002 Apr; 87(4): 1502–8

    Article  PubMed  CAS  Google Scholar 

  121. Greenspan SL, Emkey RD, Bone III HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002 Dec 3; 137(11): 875–83

    PubMed  CAS  Google Scholar 

  122. Greenspan SL, Resnick NM, Parker RA. Combination therapy for prevention/treatment of osteoporosis in elderly women: a randomized, double-blind, placebo-controlled, NIH-sponsored clinical trial [abstract no. 1040]. J Bone Miner Res 2002 Sep; 17 Suppl. 1: S135

    Google Scholar 

  123. Frediani B, Allegri A, Bisogno S, et al. Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis: two years of continuous treatment. Clin Drug Invest 1998 Mar; 15(3): 235–44

    Article  CAS  Google Scholar 

  124. Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002 Mar; 87(3): 985–92

    Article  PubMed  CAS  Google Scholar 

  125. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003 Sep 25; 349(13): 1207–15

    Article  PubMed  CAS  Google Scholar 

  126. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000 Feb 28; 160(4): 517–25

    Article  PubMed  CAS  Google Scholar 

  127. Greenspan S, Field-Munves E, Tonino R, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2002 Oct; 77(10): 1044–52

    Article  PubMed  CAS  Google Scholar 

  128. Eisman J, Rizzoli R, Gaines KA, et al. Upper GI tolerability of alendronate (FOSAMAX) 70 mg once weekly is similar to placebo [abstract no. M353]. J Bone Miner Res 2002 Sep; 17 Suppl. 1: S474

    Google Scholar 

  129. Greenspan SL, Bone III G, Schnitzer TJ, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002 Nov; 17(11): 1988–96

    Article  PubMed  CAS  Google Scholar 

  130. Biswas PN, Wilton LVW, Shakir SAW. Pharmacovigilance study of alendronate in England. Osteoporos Int 2003; 14(6): 507–14

    Article  PubMed  CAS  Google Scholar 

  131. Siris E. Alendronate in the treatment of osteoporosis: a review of the clinical trials. J Womens Health Gend Based Med 2000 Jul–Aug; 9(6): 599–606

    Article  PubMed  CAS  Google Scholar 

  132. Donahue JG, Chan KA, Andrade SE, et al. Gastric and duodenal safety of daily alendronate. Arch Intern Med 2002 Apr 22; 162(8): 936–42

    Article  PubMed  CAS  Google Scholar 

  133. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. New Engl J Med 1996 Oct; 335: 1016–21

    Article  PubMed  Google Scholar 

  134. Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: prevalence of gastrointestinal complaints, non-compliance with patient instructions, and discontinuation. J Manage Care Pharm 1998 Sep; 4(5): 488–92

    Google Scholar 

  135. Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002 Oct; 77(10): 1031–43

    Article  PubMed  Google Scholar 

  136. Lanza F, Sahba B, Schwartz H, et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol 2002 Jan; 97(1): 58–64

    Article  PubMed  CAS  Google Scholar 

  137. Lanza F, Rack MF, Simon TJ, et al. Effects of alendronate on gastric and duodenal mucosa. Am J Gastroenterol 1998; 93(5): 753–7

    Article  PubMed  CAS  Google Scholar 

  138. Lanza FL, Hunt RH, Thomson ABR, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119(3): 631–8

    Article  PubMed  CAS  Google Scholar 

  139. de Papp AE, Palmisano J, Geba GP. Upper GI tolerability of once-weekly alendronate 70 mg with concomitant NSAID use [abstract no. M350]. J Bone Miner Res 2002 Sep; 17 Suppl. 1: S473

    Google Scholar 

  140. Chrischilles EA, Dasbach EJ, Rubenstein LM, et al. The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial. Osteoporos Int 2001; 12(8): 654–60

    Article  PubMed  CAS  Google Scholar 

  141. Johnell O, Jonsson B, Jonsson L, et al. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003; 21(5): 305–14

    Article  PubMed  Google Scholar 

  142. Goldman L, Garber AM, Grover SA, et al. Task force 6: cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996; 27(5): 1020–30

    Article  PubMed  CAS  Google Scholar 

  143. Borgström F, Johnell O, Jonsson B, et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in the UK [abstract no. OC37]. Osteoporos Int 2003 Nov; 14 (Suppl. 7): S13

    Google Scholar 

  144. Mullins C, Ohsfeldt RL. Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J Manage Care Pharm 2003 Mar–Apr; 9(2): 150–8

    Google Scholar 

  145. Gao X, Madhavan S, Nau D, et al. Applying background risk distribution to evaluate the cost-effectiveness of three preventive drug therapies for osteoporotic fractures. Value Health 2001 Mar-Apr; 4(2): 70

    Article  Google Scholar 

  146. Grima DT, Burge RT, Becker DL, et al. Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. P & T 2002; 27(9): 448–55

    Google Scholar 

  147. Wehren LE, Hosking D, Hochberg MC, et al. Adjusted indirect comparisons to assess the relative efficacy of osteoporosis treatments [abstract no. P271]. Osteoporos Int 2003 Nov; 14 (Suppl. 7): S75

    Google Scholar 

  148. Zethraeus N, Ben Sedrine W, Caulin F, et al. Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 2002; 13(11): 841–57

    Article  PubMed  CAS  Google Scholar 

  149. Centers for Disease Control and Prevention. Osteoporosis among estrogen-deficient women — United States, 1988–1994. Morb Mortal Wkly Rep 1998 Nov 20; 47(45): 969–73

    Google Scholar 

  150. Harrington JT, Broy SB, Derosa AM, et al. Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum 2002 Dec 15; 47(6): 651–4

    Article  PubMed  Google Scholar 

  151. Liel Y, Castel H, Bonneh DY. Impact of subsidizing effective anti-osteoporosis drugs on compliance with management guidelines in patients following low-impact fractures. Osteoporos Int 2003; 14(6): 490–5

    Article  PubMed  CAS  Google Scholar 

  152. Andrade SR, Majumdar SM, Chan A, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 2003 Sep 22; 163: 2052–7

    Article  PubMed  Google Scholar 

  153. Delmas PD. How should the risk of fracture in postmenopausal women be assessed? Osteoporos Int 1999; 9 Suppl. 1: S33–9

    Article  PubMed  Google Scholar 

  154. ACOG Committee opinion #270. Bone density screening for osteoporosis. American College of Obstetricians and Gynecologists. Obstet Gynecol 2002 Mar; 99(3): 523–5

    Article  Google Scholar 

  155. ClinicalTrials.gov. EVA: Evista Alendronate comparison [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2003 Jul 30]

  156. Compston JE, Watts NB. Combination therapy for postmenopausal osteoporosis. Clin Endocrinol (Oxf) 2002; 56(5): 565–9

    Article  CAS  Google Scholar 

  157. Khosla S. Parathyroid hormone plus alendronate — a combination that does not add up. N Engl J Med 2003 Sep; 349(13): 1277–9

    Article  PubMed  Google Scholar 

  158. Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002 Nov; 24(11): 1871–86

    Article  PubMed  CAS  Google Scholar 

  159. Guyatt GH, Cranney A, Griffith L, et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am 2002; 31(3): 659–79

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Inc., 770 Township Line Road, Suite 300, Yardley, Pennsylvania, PA 19067, USA

    Susan J. Keam & Greg L. Plosker

Authors
  1. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Greg L. Plosker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan J. Keam.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keam, S.J., Plosker, G.L. Prevention and Treatment of Osteoporosis in Postmenopausal Women. Dis-Manage-Health-Outcomes 12, 19–37 (2004). https://doi.org/10.2165/00115677-200412010-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200412010-00003

Keywords

Search

Navigation